Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human EGF-rP64K + Montanide ISA 51
- Development stage
- Unknown
- Lead developer
- Center for Molecular Immunology
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A therapeutic cancer vaccine composed of recombinant human epidermal growth factor (rEGF) conjugated to the carrier protein rP64K (derived from Neisseria meningitidis), and emulsified with the adjuvant Montanide ISA 51. The vaccine is designed to induce a humoral immune response against both the exogenous rEGF and endogenous EGF, leading to antibody-mediated inhibition of endogenous EGF binding to its receptor, epidermal growth factor receptor (EGFR). This mechanism may result in reduced tumor cell proliferation. The formulation uses Montanide ISA 51 as an adjuvant, which enhances immunogenicity by creating a depot effect at the injection site for slow antigen release and strong activation of CD4+ and CD8+ T cells. It has been primarily investigated for use in non-small cell lung cancer and other cancers[7][10].
- Brand names
- CimaVax EGFCIMAvax Epidermal Growth Factor VaccineCIMAvax IMCIMAvax-EGF
- Other names
- recombinant human EGF-rP64K/Montanide ISA 51 vaccine
02
Targets
Beyond the preview
Go deeper on recombinant human EGF-rP64K + Montanide ISA 51.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human EGF-rP64K + Montanide ISA 51.